康格林素通过抑制PDGFR来抵消血管光滑肌肉细胞脱差和相关的动脉硬化
Shuang Yang1, Yixiu Zhao1, Shifeng Cao1
1State Key Laboratory of Frigid Zone Cardiovascular Diseases (SKLFZCD), Department of Pharmacology (State Key Labratoray -Province Key Laboratories of Biomedicine-Pharmaceutics of China, Key Laboratory of Cardiovascular Research, Ministry of Education), College of Pharmacy, Harbin Medical University, Harbin 150081, China.
康格莱克辛 (KLX) 通过抑制血管光滑肌细胞 (VSMC) 不分化,有效治疗动脉样硬化和动脉新极限形成. 这种新型化合物向PDGFR-β信号通路,为VSMC相关疾病提供了有前途的治疗方法.
科学领域:
- 心血管生物学 心血管生物学
- 药理学 药理学是指药理学的学科.
- 分子医学是分子医学.
背景情况:
- 血管光滑肌细胞 (VSMC) 功能障碍是动脉样硬化和增生等疾病的基础.
- 目前针对VSMC的药物缺乏特异性,需要新的治疗剂.
- 康莱克辛 (KLX) 是一种新型的人类,显示出调节VSMC表型的潜力.
研究的目的:
- 评估KLX在VSMC脱差和动脉样硬化的治疗效果.
- 为了调查KLX在新极端形成中的作用.
- 阐明 KLX 的作用背后的分子机制.
主要方法:
- 动脉样硬化模型:ApoE-/-小鼠在13周的高脂肪饮食中.
- 新极端形成模型:老鼠动脉气球损伤.
- 在体外:PDGF-BB诱导VSMC脱差.
主要成果:
- 在小鼠中,KLX改善了动脉样硬化病变,脂质和原沉积.
- KLX减少了老鼠动脉中受伤后的neointimal形成.
- 分子对接和SPR证实KLX与PDGFR-β结合,激活PDGFR-β-MEK-ERK-ELK-1/KLF4通路,以抑制VSMC的增殖,迁移和脱差.
结论:
- 通过抑制VSMC表型转换,KLX可以减轻动脉样硬化和新极端形成.
- 这种机制涉及PDGFR-β-MEK-ERK-ELK-1/KLF4信号通路.
- KLX显示出作为与VSMC表型变化相关的动脉样硬化治疗剂的显著潜力.
更多相关视频
08:28Isolation of Primary Patient-specific Aortic Smooth Muscle Cells and Semiquantitative Real-time Contraction Measurements In Vitro
Published on: February 15, 2022
07:15Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway
Published on: August 23, 2024
相关概念视频
Antihypertensive Drugs: Vasodilators
Regulation of Angiogenesis and Blood Supply
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Antihypertensive Drugs: Action of Calcium Channel Blockers
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Antihypertensive Drugs: Angiotensin II Receptor Blockers
